Genmab | GEN - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Almirall EUR 531.16M 13.76M 2026-06
Amarin USD 51.48M 113K 2025-12
Amgen USD 11.69B 6.9B 2026-06
argenx SE USD 1.02B 118M 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
Bayer EUR 10.04B 168M 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Demant DKK 10.79B 1.16B 2026-06
Exelixis USD 380.28M 20.8M 2026-06
Fresenius Medical Care EUR 4.32B 20.7M 2026-06
Genmab DKK 748M 77M 2026-06
GlaxoSmithKline GBP 5.8B 468M 2026-06
GN Store Nord DKK 2.11B 51M 2026-06
GRIFOLS EUR 1.55B 94M 2026-06
Hikma Pharmaceutical USD 1.34B 702M 2025-12
Insmed USD 526.79M 20.55M 2026-06
Lakefront Biotherapeutics EUR 55.62M 14.56M 2026-06
Lonza CHF 2.9B 184M 2025-06
Merck EUR 4.34B 249M 2026-06
Novartis USD 10.2B 912M 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Sanofi EUR 9.92B 607M 2026-06
UCB EUR 2.96B 196M 2025-12